Silo Pharma (NASDAQ:SILO) and Cronos Group (NASDAQ:CRON) Head to Head Survey

Silo Pharma (NASDAQ:SILO) and Cronos Group (NASDAQ:CRON) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, profitability, analyst recommendations, risk and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Silo Pharma and Cronos Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silo Pharma	1	0	0	0	1.00
Cronos Group	0	1	3	1	3.00

Cronos Group has a consensus price target of $2.30, indicating a potential downside of 31.34%. Given Cronos Group’s stronger consensus rating and higher possible upside, analysts plainly believe Cronos Group is more favorable than Silo Pharma.

Volatility & Risk

Silo Pharma has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, Cronos Group has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.

Insider & Institutional Ownership

5.6% of Silo Pharma shares are owned by institutional investors. Comparatively, 8.7% of Cronos Group shares are owned by institutional investors. 3.6% of Silo Pharma shares are owned by company insiders. Comparatively, 7.8% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Silo Pharma and Cronos Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Silo Pharma	-6,726.39%	-81.75%	-66.35%
Cronos Group	39.08%	4.85%	4.62%

Valuation & Earnings

This table compares Silo Pharma and Cronos Group”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silo Pharma	$54,077.00	34.65	-$4.23 million	($4.36)	-0.27
Cronos Group	$146.59 million	8.42	-$9.45 million	$0.20	16.75

Silo Pharma has higher earnings, but lower revenue than Cronos Group. Silo Pharma is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Summary

Cronos Group beats Silo Pharma on 13 of the 15 factors compared between the two stocks.

About Silo Pharma

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

About Cronos Group

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.